Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Lymphoma, T-Cell, Cutaneous 8Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Burkitt Lymphoma 4Melanoma 3Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Vomiting 2Uveal Melanoma 2Testicular Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neuroblastoma 2Neoplasms 2Nausea 2Myeloproliferative Disorders 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

cabozantinib 2Everolimus 2veliparib 1vatalanib 1temsirolimus 1sargramostim 1rovalpituzumab tesirine 1pentetreotide 1cixutumumab 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Salts 1Octreotide 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Dexamethasone 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Dexamethasone × Dermatologic × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡